Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3421 - Apatinib as a salvage treatment in gynecologic cancer patients failed from two or more lines of prior chemotherapy

Date

09 Sep 2017

Session

Poster display session

Topics

Clinical Research;  Gynaecological Malignancies

Presenters

Congying Xie

Citation

Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372

Authors

C. Xie1, X. Jin2

Author affiliations

  • 1 Radiotherapy And Chemotherapy, the 1st Affiliated Hospital of Wenhzou Medical University, 325000 - Wenhou/CN
  • 2 Radiotherapy And Chemotherapy, the 1st Affiliated Hospital of Wenhzou Medical Univeristy, 325000 - Wenzhou/CN
More

Resources

Abstract 3421

Background

Apatinib is an oral inhibitor of the vascular endothelial growth factor receptor (VEGFR)-2. There is currently no standard treatment for patients with gynecologic cancer who failed from ≥2 lines of chemotherapy. The purpose of this study is to evaluate the benefits and adverse events of apatinib in the treatment of patients with advanced cervical and ovarian cancer who failed from ≥2 lines of chemotherapy.

Methods

Patients with advanced cervical and ovarian cancer received at least two lines of prior chemotherapy before being treated with apatinib were retrospectively reviewed between April 2015 and January 2017. All included patients received continuous apatinib treatment until disease progression, death, or intolerable toxicity. Prognosis and toxicities were evaluated by the Kaplan-Meier method and according to NCI-CTC 3.0, respectively.

Results

Twenty-six patients were eligible (cervical cancer, n = 12 (46.2%); ovarian cancer, n = 14 (53.8%)). After apatinib dose adjustment, 14 patients (53.8%) received 500 mg/day, 8 received 250 mg/day, 3 received 425 mg/day, and one received 675 mg/day. The median progression-free survival (PFS) of cervical and ovarian cancer was 8 months (95% confidence interval (CI): 3.83-12.17) and 4 months (95%CI:1.57-6.44), respectively. The objective response rates in cervical cancer and ovarian cancer were 50% (n = 6/12) and 50% (n = 7/14), respectively. The disease control rates were 100% (n = 12/12) for cervical cancer and 71.4% (n = 10/14) for ovarian cancer. No complete response was observed. The toxicities associated with apatinib were generally acceptable: eight patients (30.8%) developed grade 3/4 toxicity. The most common adverse events were hypertension (n = 17; 65.4%), hand-foot syndrome (n = 24, 92.3%), and mouth mucositis (n = 20, 76.9%).

Conclusions

Apatinib monotherapy could be a promising and tolerable treatment for patients with advanced/recurrent cervical and ovarian cancer who failed from two or more lines of chemotherapy.

Clinical trial identification

Legal entity responsible for the study

Congying Xie

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.